Analysis of One-Year Cancer Survival Rates

NHS West Essex CCG Profile
The Public Health Action Support Team (PHAST) has undertaken this research.

Transforming Cancer Services Team for London, commissioned the work.

Commissioner Lead Contact Details

Name: Andy McMeeking

Role: Team Manager – Transforming Cancer Services Team for London

Email: andy.mcmeeking@nhs.net
3.2.2 Healthy life expectancy at birth and 65 years .............................. 27

3.3 Early diagnosis measures ..................................................................... 29

3.3.1 Screening measures; breast and bowel ........................................... 30

3.3.1.1 Breast cancer screening ............................................................ 30

3.3.1.2 Bowel cancer screening ........................................................... 32

3.3.2 Use of the urgent referral pathway .................................................. 33

3.3.3 Emergency presentations ............................................................... 37

3.3.3.1 Proxy measure for emergency presentations for cancer .................... 38

3.3.3.2 Rate of emergency admissions with cancer .................................. 38

3.3.4 Routes to diagnosis ......................................................................... 40

3.3.5 Stage at diagnosis ............................................................................ 41

3.3.5.1 Prevalent cancer cases ............................................................... 41

3.3.5.2 Cancer Staging .......................................................................... 42

3.4 Diagnostics and treatment ................................................................. 43

3.4.1 6 week waits for key diagnostics ..................................................... 43

3.4.2 Access to diagnostic procedures .................................................... 45

3.4.3 Cancer waiting times ...................................................................... 47

3.4.3.1 2 week wait, all cancer (patients waiting within 14 days) ................. 47

3.4.3.2 31-day (diagnosis to treatment) wait for first treatment, all cancers .......... 48

3.4.3.3 62-day (urgent GP referral) wait for first treatment, all cancer .......... 49

3.4.4 Key provider performance ............................................................ 50
3.5 Explanatory factors: summary of section ................................................................. 54

4. Next steps ......................................................................................................................... 58
Executive Summary

This report considers cancer survival and other measures related to cancer from a variety of statistics, for all cancers and for three main cancers - breast, lung and colorectal, and for different age groups. The results give an indication of how well West Essex residents are being screened, diagnosed and treated for cancer in comparison with those in the rest of London and West Essex and in comparison with England averages. The findings indicate where the CCG may want to examine further or take action in their commissioning processes.

The index of one-year net survival from all cancers provides a convenient, single number that summarises the overall patterns of cancer survival, for a wide range of cancers with very disparate survival.

The methodology has been developed by the Cancer Survival Group (CSG) at London School of Hygiene and Tropical Medicine, this team being recognised as a centre of excellence within the UK and internationally, for the production of cancer survival statistics.

The all-cancers net survival index is adjusted for changes over time in the profile of cancer patients by age, sex and type of cancer. This is because survival varies widely with these three factors. The cancer net survival index is modelled to take into account likely mortality from non-cancer causes, using deprivation adjusted life tables.

The one-year survival index data is for the period 1997 to 2012, with site-specific figures for the period 2008 to 2012. The explanatory measures presented follow these periods as closely as possible using the latest and most appropriate data available.

The one-year net survival index for all cancers combined in West Essex has increased over the period to 68.4% in 2012 (latest data available from ONS),
and the published figures show this to be lower than the London average of 69.7% and the overall England figure of 69.3%. The 2012 measure shows West Essex as having a low net survival amongst London CCGs (ranking 24th; 1 highest, 33 lowest).

The following explanatory measures will have positively impacted on the average level of one-year net survival from all cancers for West Essex:

- For both males and females, at birth and aged 65 years, healthy life expectancy in West Essex is higher than that for England
- Breast cancer screening coverage was very similar in West Essex compared with the England average over the period 2012 – 2014. Uptake for breast cancer screening was slightly higher in West Essex than the England average
- West Essex residents in the 60-69 years target age group consistently have very similar coverage and uptake for bowel cancer screening to that for England as a whole
- The rate of urgent referrals per 100,000 population (referred using the two-week wait urgent referral pathway) increased in West Essex across the three years 2012 - 2014 and was consistently higher than that for England overall
- The detection rate tells us the percentage of all cancers that were identified through the two-week wait pathway. This was approximately 50% in West Essex over the period 2012 – 2014 with the rate consistently above the England rate
- Less than a fifth of West Essex cancer patients presented as emergencies according to the NCIN proxy measure. The percentage has fluctuated around this level during 2008 - 2012 and was consistently lower than that for England as a whole
The rate of emergency admissions with cancer per 100,000 population was lower for West Essex than England as a whole for 2012 and 2013. In keeping with the rate for England overall, there was a large drop in the rate in West Essex from 2012 to 2013.

The proportion of breast cancers detected through screening was higher in West Essex than for England;

The proportion of colorectal cancers detected through each of the routes reported was very similar in West Essex compared with England.

The prevalent cancer cases (% of practice population on practice cancer registers) for West Essex residents in each of the three years 2012, 2013 and 2014 was higher than the England value.

The latest staging data from the Cancer Outcomes and Services Dataset (COSD) shows higher percentages of cancers diagnosed at early stages (stages 1 and 2) for West Essex residents than for London overall. The proportion diagnosed with an unknown stage is lower than that across London.

The proportions of people in West Essex waiting more than six weeks for colonoscopy, flexible sigmoidoscopy and gastroscopy procedures tended to be below the proportions for London and West Essex overall.

The percentage of non-small cell lung cancer (NSCLC) patients with cancer at stages 1a to 2b receiving surgery is considered a particular strong measure of lung cancer provider performance and here The Princess Alexandra is higher than the London average (63% compared with 52% across London).

The adjusted 18-month stoma rate is a key colorectal provider performance area and here The Princess Alexandra is lower than the London average (44% compared with 51% across London).
The following explanatory measures will have negatively impacted on the average level of one-year net survival from all cancers for West Essex and suggest areas for improvement:

- In West Essex, in 2009/10, the Cancer Awareness Measure found that 41% of people surveyed could recall a symptom of cancer. West Essex is ranked as 17th out of the 22 CCGs with survey results.

- The conversion rate is the percentage of referrals that were found to have cancer and provides an indicator of referral quality. The conversion rate was lower for West Essex at 8.1% in 2012 rising marginally to 8.2% in 2014 against the England figure of 9.5% in 2014.

- The proportion of breast cancers detected through the managed route was lower in West Essex than for England and the ‘other’ route was higher.

- The proportion of lung cancers detected through the managed route was lower in West Essex than for England.

- The rates of access to colonoscopy, sigmoidoscopy and upper GI endoscopy procedures for West Essex residents tended to be lower than those for England over the period 2012 - 2013.

- In 2013/14, 94.6% of patients in NHS West Essex CCG saw a specialist within two weeks. Whilst above the standard set for England (93%), this is lower than the England average (95.3%)

- In 2013/14, 98.1% of cancer patients in NHS West Essex CCG received their first treatment within 31 days of a decision to treat. This is slightly lower than the England average (98.2%)

- In 2013/14, 82.8% of cancer patients in NHS West Essex CCG received their first treatment within 62 days of an urgent GP referral. This is lower than the England average (85.8%)
• The percentage of patients having CT prior to bronchoscopy is considered a strong measure of lung cancer provider performance and here The Princess Alexandra is lower than the London average (93.7% compared with 95% across London)

• The adjusted 90-day post op mortality is strong measure of colorectal cancer provider performance and here The Princess Alexandra is higher than the London and the audits average (8.3% compared with 4.6%).
1. **Introduction**

Cancer is the cause group responsible for the majority of avoidable deaths in England and Wales\(^1\). As such it is unsurprising that cancer indicators feature prominently in the national set of outcome indicators for Clinical Commissioning Groups (CCGs)\(^2\). Section 1 of the 2015/16 CCG Outcomes Indicator Set focuses on preventing people from dying prematurely and 8 of the 24 indicators relate to cancer. The primary focus of this report is two of these measures - one-year survival from all cancers and one-year survival from breast, lung & colorectal (bowel) cancers.

Clinical Commissioning Groups (CCGs) have been requested by NHS England (London) as part of the Key Lines of Enquiry (KLoE) to CCG narratives for 2015/16 operational plans to explain how they will track one-year net cancer survival rates and to detail their plans for improving this key measure. This report has been produced to help the CCG Board to meet this request; it examines the one-year net survival index for adults in West Essex alongside a range of explanatory factors, and identifies areas and actions for improvement.

The Transforming Cancer Services Team (TCST) for London has commissioned PHAST to report on, for each of the 33 London and West Essex CCGs, an in-depth analysis of current positions and trends in one-year cancer survival. A range of explanatory factors has been considered to identify areas for improvement, and where relevant, recommendations are made to enable CCGs to target interventions to improve cancer awareness and screening, diagnosis and treatment.

The report is in two parts:

---


1. The one-year net survival index - here we provide an overview of the index and report on current positions and trends across the 33 London and West Essex CCGs

2. The explanatory factors - here we review how well West Essex has performed across a wide range of measures (thirty-three). These measures cover the National Awareness and Early Diagnosis Initiative (NAEDI) pathway and are grouped into three themes: public awareness, early diagnosis and treatment.

The report uses routinely available data sources such as the National Cancer Intelligence Network (NCIN) GP practice profiles. London data is provided as a comparator alongside trend data for the CCG; where London figures were not available we have used published national data. The data periods used in the report were selected on the basis of a combination of timeliness and relevance to the periods covered by the net survival index (1997 – 2012 for the one-year survival index and 2008 – 2012 for the site specific indices).
2. The one-year cancer net survival index

2.1 Overview of section

CCGs have been requested by NHS England to explain how they will track one-year cancer survival and to detail their plans for improving this key measure. This part of the report provides an overview of the index and presents findings for London and West Essex CCGs. In this section we report on:

- Background to the one-year net survival index for all cancers combined
- Overall (all-ages) net survival
- Site specific levels of survival: lung, colorectal and breast
- Survival by age group: all adults (15-99 years), 55-64 years, 75-99 years
- Summary.

2.2 Background to the one-year cancer net survival index

The one-year cancer net survival index has been developed to provide a robust high-level summary measure. It is included in the CCG Outcomes Indicator Set\(^3\) and the All Party Parliamentary Committee on Cancer\(^4\) campaigned for it to be included in the Delivery Dashboard of the 2015/16 Clinical Commissioning Group (CCG) Assurance Framework\(^5\). Indeed, the NHS operating plan for CCGs (the Forward View into Action) includes the fundamental requirement for plans to improve early diagnosis for cancer and to track one-year cancer survival\(^6\).

The index of one-year survival from all cancers combined provides a convenient, single number that summarises the overall patterns of survival for

---

\(^3\)http://www.england.nhs.uk/resources/resources-for-ccgs/ccg-out-tool/ccg-ois/ last accessed 22 October 2015
\(^4\)http://www.macmillan.org.uk/GetInvolved/APPG/APPG.aspx last accessed 22 October 2015
\(^5\)http://www.england.nhs.uk/commissioning/ccg-auth/ last accessed 16 October 2015
cancers newly diagnosed each calendar year, for a wide range of cancers with very disparate survival. Survival for most cancers is either stable or rising steadily from year to year\(^1\). This trend is reflected in the values of the index in the tables produced by ONS. However, patterns of cancer occurrence by age, sex and type of cancer, can shift quite quickly over time, especially in small areas. The survival index is designed to reflect real progress (or otherwise) by providing a summary measure of cancer survival that adjusts for any such shifts. It is intended to change only if cancer survival itself actually changes and hence is a good measure. It is designed for long-term monitoring of progress in overall cancer survival.

Indicator values are published on the ONS website\(^1\). The Cancer Survival Group (CSG) at LSHTM has developed the methodology for the indicators. ONS commissions cancer survival figures from the CSG, since this team is recognised as a centre of excellence within the UK for the production of cancer survival statistics.

To make figures from the past comparable with those for today and in the future, the all-cancers survival index is adjusted for changes over time in the profile of cancer patients by age, sex and type of cancer. This is because survival varies widely with all three factors.

Overall cancer survival can change simply because the profile of cancer patients changes, even if survival at each age, for each cancer and in each sex has not changed. This adjustment is made by using a weighted average of all the cancer survival estimates for each age, sex and cancer, using the proportions of cancer patients diagnosed in England and Wales during 1996–99 in each age group, sex and type of cancer as the standard weights. All values of the cancer survival index, past and future, are adjusted using the same standard weights. This means that the cancer survival index is not affected by changes over time in the proportion of cancers of different lethality in either sex (for example, a reduction in lung cancer or an increase in breast cancer). Similarly, the index will be unaffected by a change in the age profile
of newly diagnosed cancer patients, or a shift in the proportion of a given type of cancer between men and women.

The cancer net survival index is modelled to take into account likely mortality from non-cancer causes. Adjustment of life tables for area deprivation takes an account of differences between areas in levels of relative deprivation.

The one-year survival index (%) for all cancers combined is available by calendar year of diagnosis, by CCG, Area Team and England. All adults (15 – 99 years) who were diagnosed with a first, primary, invasive malignancy were eligible for inclusion. Patients diagnosed with malignancy of the skin other than melanoma are excluded. Cancer of the prostate was also excluded from the index, because the widespread introduction of prostate-specific antigen (PSA) testing since the early 1990s has led to difficulty in the interpretation of survival trends (Pashayan et al., 2006).

Further details on the index methodology, published data and figures can be found on the ONS website.
2.3 Overall all ages net survival measure

The one-year all ages (15-99 years) net cancer survival measure for London CCGs has been reviewed and we have summarised the available data (1997 to 2012) in the following at a glance ‘RAG rating’ table.

The ‘RAG rating’ was developed by categorising the index values on the basis of comparison with the England value as being either:

- Red (the CCG value is low compared with England)
- Amber (the CCG value is broadly comparable with England)
- Green (the CCG value is better than that for England).

The detailed data on which the RAG rating table is based is available on the ONS website.

The table below gives a summary ‘RAG rating’ for the overall all adults one-year net survival measure (15-99 years) alongside similar for 55-64 years and 75-99 years age groups.
Table 1: Summary of one-year net survival index by CCG

<table>
<thead>
<tr>
<th>CCG</th>
<th>15-99ys</th>
<th>55-64ys</th>
<th>75-99ys</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barking and Dagenham</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bexley</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bromley</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Camden</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central London (Westminster)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City and Hackney</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croydon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ealing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enfield</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greenwich</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hammersmith and Fulham</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haringey</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harrow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Havering</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hillingdon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hounslow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Islington</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kingston</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lambeth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lewisham</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merton</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newham</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Redbridge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richmond</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southwark</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sutton</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tower Hamlets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waltham Forest</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wandsworth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>West London</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>West Essex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend**
- CCG consistently above England values
- CCG trend line crossing England trend line
- CCG consistently below England values

*Underlying data source: London School of Hygiene and Tropical Medicine, published on ONS website.*
The one-year net survival index for all cancers combined in West Essex has increased over the period to 68.4% in 2012 (latest data available from ONS), and the published figures show this to be lower than the London average of 69.7% and the overall England figure of 69.3%. The 2012 measure shows West Essex as having a low net survival amongst London CCGs (ranking 24th; 1 highest, 33 lowest).

2.4 Site specific levels of survival: lung, colorectal and breast

The survival index will only change over time (or between areas) if the levels of survival for the particular cancer site or age group change over time (or between areas). In this section trends in the three main cancers are provided (lung, colorectal and breast).

These are chosen as between them they account for 39% of cancer mortality (based on 2012 The 20 Most Common Causes of Cancer Death in 2012 Number of Deaths per Year, All Ages, UK7). Lung cancer is by far the most common cause of cancer death in the UK. More than one in five (22%) cancer deaths are from lung cancer. Bowel cancer is the second most common cause of cancer death (10%) and, breast cancer is the third most common cause of cancer deaths overall (7%).

2.4.1 Lung cancer

The one-year lung cancer net survival for West Essex increased from 30.4% in 2008 to 31.9% in 2012 (latest data available from ONS) lower than the overall England figure of 33.4%. The 2012 measure shows West Essex as being in the bottom quartile of net survival amongst London CCGs (ranking 27th; 1 highest, 33 lowest).

**Figure 1: One-year net survival index for lung cancer, aged 15-99 years**

Source: London School of Hygiene and Tropical Medicine, published on ONS website.

### 2.4.2 Colorectal Cancer

One-year survival from colorectal cancer in West Essex was, over the 2008 - 2012 period considered, lower than that for England as a whole. The one-year colorectal cancer net survival for West Essex increased, in line with the upward trend for England as a whole, to 75.8% in 2012 (latest data available from ONS) where it remained lower than the overall England figure of 77.3%. The 2012 measure shows West Essex as being one of the lowest net survival amongst London CCGs (ranking 25th; 1 highest, 33 lowest).
**Figure 2: One-year net survival index for colorectal cancer, aged 15-99 years**

Source: London School of Hygiene and Tropical Medicine, published on ONS website.

### 2.4.3 Breast Cancer

One-year survival from breast cancer in West Essex was, over the 2008 - 2012 period considered, similar to England as a whole. Net survival for West Essex, in line with the trend for England as a whole, increased over the period from 94.5% in 2008 to 94.8% in 2012 (latest data available from ONS) lower than the overall England figure of 96.4%. The 2012 measure shows West Essex as having a low net survival amongst London CCGs (ranking 30th; 1 highest, 33 lowest).
For all three cancers there is room for survival improvement; however this is particularly the case for breast cancer.

2.5 Age group levels of survival: all adults, 55-64ys and 75-99ys

As stated previously, the survival index will only change over time (or between areas) if the levels of survival for a particular cancer or age group change over time (or between areas). In this section trends in all adults, in the 55-64 years age group and in the 75-99 years age groups are detailed.

The cancer one-year net survival publications include data on the specific age groups 55-64 years old and 75-99 years old alongside all adults (15-99 years). The 55-64 years age group is of particular interest as this is a key age group in terms of opportunities for maximising survival. More than a third of cancers are diagnosed in people aged 75 and over making this also a key age group for consideration.

Source: London School of Hygiene and Tropical Medicine, published on ONS website.

8 [http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-Two](http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-Two)
2.6 One-year survival index for all cancers, all adults aged 15-99

The adult (15-99 years old) one-year net survival index for all cancers has risen steadily at England, regional (London) and local (West Essex) levels. Nationally, one-year cancer net survival increased from 59.7% in 1997 to 69.3% in 2012, an increase of just under 10%. The increase in West Essex has been lower than that for England as a whole (and London overall), increasing from 60.2% in 1997 to 68.4% in 2012, an increase of 8.2%.

Figure 4: One-year survival index for all cancers combined, aged 15-99 years

Source: London School of Hygiene and Tropical Medicine, published on ONS website.

2.7 One-year survival index for all cancers, adults aged 55-64

The one-year net survival index for all cancers has increased in the 55-64 years age group at England, regional (London) and local (West Essex) levels. The increase in the index for 55-64 year olds in West Essex was less than that for England as a whole. At England level, the index in the 55-64 years age group increased from 66.8% in 1997 to 76.7% in 2012 (up 9.9%). In West Essex the index increased from 69.3% in 1997 to 77.1% in 2012 (up 7.8%).
Figure 5: One-year survival index for all cancers combined, aged 55-64 years

Source: London School of Hygiene and Tropical Medicine, published on ONS website.

2.8 One-year survival index for all cancers, adults aged 75-99 years old

In older people (75-99 years old) one-year net survival index has risen at England, regional (London) and local (West Essex) levels. Nationally, one-year cancer net survival increased from 47.4% in 1997 to 57.2% in 2012, an increase of just under 10%. The increase in West Essex has been less than that for England as a whole (and London overall), increasing from 45.6% in 1997 to 54.8% in 2012, an increase of 9.2%.
2.9 The one-year cancer net survival index: summary of section

The index of one-year survival from all newly diagnosed cancers provides a convenient, single number that summarises the overall patterns of cancer survival in each calendar year, for a wide range of cancers with very disparate survival.

The all-cancers survival index is adjusted for changes over time in the profile of cancer patients by age, sex and type of cancer. This is because survival varies widely with all three factors. The cancer survival index is not affected by changes over time in the proportion of cancers of different lethality in either sex (for example, a reduction in lung cancer or an increase in breast cancer). Similarly, the index will be unaffected by a change in the age profile of newly diagnosed cancer patients, or a shift in the proportion of a given type of cancer between men and women.

The one-year net survival index for all cancers combined in West Essex has increased over the period to 68.4% in 2012 (latest data available from ONS),
and the published figures show this to be lower than the London average of 69.7% and the overall England figure of 69.3%. The 2012 measure shows West Essex as having a low net survival amongst London CCGs (ranking 24th; 1 highest, 33 lowest).

One year survival rates for the ‘big’ cancers have improved (2008-2012) but are consistently low in terms of London ranking (lung 27th, colorectal 25th, breast 30th, across 33 London and West Essex CCGs).
3. The explanatory factors

In this section we review how well West Essex has performed across a wide range of measures (thirty-three); these were chosen by the project team (PHAST and TCST) as they cover the ‘NAEDI pathway’ and are routinely available, making updating of the charts possible at a local level. This section presents:

- An overview of NAEDI and the NAEDI pathway
- Public awareness measures
- Early diagnosis measures
- Diagnostics and treatment measures.

3.1 An overview of the National Awareness and Early Diagnosis Initiative

The National Awareness and Early Diagnosis Initiative (NAEDI) is a public sector/third sector partnership led by Cancer Research UK, the Department of Health, NHS England and Public Health England. NAEDI formally launched in 2008 and continues as a partnership between public and third sector organisations. Its role is to provide leadership and support to activities and research that promote earlier diagnosis of cancer.

When cancer is diagnosed at an early stage, treatment options, survival and chances of a full recovery are greater. Over 93% of bowel cancer patients diagnosed with the earliest stage of disease survive at least five years compared with less than 7% of those diagnosed with the most advanced stage disease. The same pattern is true for lung cancer, breast cancer, and for many cancers, common or rare. We know that inequalities exist, with some groups of patients more likely to be diagnosed with later stage disease.

The National Awareness and Early Diagnosis Initiative (NAEDI) was set out as a priority in the national strategy Improving Outcomes: A Strategy for Cancer (January 2011). The initiative promotes an evidence based pathway approach comprising of three key themes:

- Public awareness;
- Early diagnosis; and
- Diagnostics and treatment.

These three themes are used in the subsequent sections to structure our presentation of a wide range of measures that have been investigated to explain variation in the overall net survival measure.

3.2 Public awareness measures

When members of the public raise concerns and present possible symptoms to clinicians, the opportunities for early detection and treatment of less advanced cancers are increased. The National Awareness and Early Diagnosis Initiative (NAEDI) pathway starts with people knowing the signs of cancer and presenting to health services to have these investigated.

In this section we consider two important areas that will impact on early presentation of possible symptoms:

- Cancer awareness - recall of a symptom of cancer (this provides a measure of knowledge of cancer symptoms) – and barriers to seeking help; and
- Healthy life expectancy (HLE).

---

3.2.1 Cancer Awareness Measures (CAM) survey

Low cancer awareness may contribute to delayed presentation, delayed diagnosis and poor cancer survival. The Cancer Awareness Measure (CAM) is a validated survey that helps to assess people's knowledge of common cancer symptoms, and their intention to seek help if they notice a warning sign of cancer. In order to develop a baseline measure for the Cancer National Awareness and Early Diagnosis Initiative (NAEDI), the CAM was used in 23 of the 31 former PCT areas (London boroughs) between 2009 and 2011. Around 18,500 people were surveyed. We can see from the table below that survey results are known for two thirds of the 33 CCGs in London and West Essex.

In West Essex, in 2009/10, the CAM found that 41% of people surveyed could recall a symptom of cancer. West Essex is ranked as 17th out of the 22 CCGs with survey results. Richmond achieved the highest percentage of respondents being able to recall a symptom of cancer (67%) and Enfield the lowest (30%).
### NHS West Essex CCG

**Table 2: National and local Cancer Awareness Measures Survey results**

<table>
<thead>
<tr>
<th>Borough</th>
<th>Unprompted recall of lump or swelling+</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>England</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barking and Dagenham</td>
<td>31%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Barnet</td>
<td>41%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Bexley</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Brent</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bromley</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Camden</td>
<td>32%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Westminster</td>
<td>49%</td>
<td>2009/10</td>
</tr>
<tr>
<td>City &amp; Hackney</td>
<td>57%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Croydon</td>
<td>60%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Ealing</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Enfield</td>
<td>30%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Greenwich</td>
<td>55%</td>
<td>2012</td>
</tr>
<tr>
<td>Hammersmith and Fulham</td>
<td>-</td>
<td>2009/10</td>
</tr>
<tr>
<td>Haringey</td>
<td>35%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Harrow</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Havering</td>
<td>57%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Hillingdon</td>
<td>*</td>
<td>2011</td>
</tr>
<tr>
<td>Hounslow</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Islington</td>
<td>44%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Kingston</td>
<td>64%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Lambeth</td>
<td>57%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Lewisham</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Merton</td>
<td>54%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Newham</td>
<td>48%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Redbridge</td>
<td>50%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Richmond</td>
<td>67%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Southwark</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sutton</td>
<td>61%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Tower Hamlets</td>
<td>42%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Waltham Forest</td>
<td>48%</td>
<td>2009/10</td>
</tr>
<tr>
<td>Wandsworth</td>
<td>52%</td>
<td>2009/10</td>
</tr>
<tr>
<td>West Essex</td>
<td>41%</td>
<td>2009/10</td>
</tr>
</tbody>
</table>

* + in response to the question: “There are many warning signs and symptoms of cancer. Please name as many as you can think of”
* Hillingdon, Bowel CAM only undertaken in 2011

The 2008 national survey of public awareness of cancer reported\(^\text{11}\) that "awareness of cancer warning signs was low when open-ended (recall) questions were used and higher with closed (recognition) questions; but on either measure, awareness was lower in those who were male, younger, and from lower socioeconomic status (SES) groups or ethnic minorities".

**3.2.1.1 Barriers to seeking help**

The report identified the most common barriers to seeking help were difficulty in making an appointment, worry about wasting the doctor’s time and worry about what would be found. “Emotional barriers were more prominent in lower SES groups and practical barriers (e.g. too busy) more prominent in higher SES groups. Anticipated delay was lower in ethnic minority and lower SES groups”.

Barriers to seeking help have been surveyed in national and local CAM surveys, with the following question posed:

"*Sometimes people put off going to see the doctor, even when they have a symptom that they think might be serious. These are some of the reasons people give for delaying. Could you say if any of these might put you off going to the doctor?*

Findings from this area of the survey are presented in the following table:

\(^{11}\)http://www.cancerresearchuk.org/sites/default/files/bjc_awareness_in_britain_0.pdf last accessed 16 October 2015
### Table 3: National and local Cancer Awareness Measures Survey results

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td><strong>2008</strong></td>
</tr>
<tr>
<td><strong>2010</strong></td>
</tr>
<tr>
<td><strong>2012</strong></td>
</tr>
<tr>
<td><strong>2014</strong></td>
</tr>
<tr>
<td><strong>2015</strong></td>
</tr>
</tbody>
</table>

- **2008** | **2010** | **2012** | **2014** | **2015** |

- **Year**
- **England**
- **All local CAM surveys**
- **Barking & Dagenham**
- **Barnet**
- **Bexley**
- **Brent**
- **Bromley**
- **Camden**
- **Westminster**
- **City & Hackney**
- **Croydon**
- **Ealing**
- **Enfield**
- **Greenwich**
- **Hammersmith & Fulham**
- **Haringey**
- **Harrow**
- **Havering**
- **Hillingdon**
- **Hounslow**
- **Islington**
- **Kingston**
- **Lambeth**
- **Lewisham**
- **Merton**
- **Newham**
- **Redbridge**
- **Richmond**
- **Southwark**
- **Sutton**
- **Tower Hamlets**
- **Waltham Forest**
- **Wandsworth**
- **West Essex**

- **Total refers to all local CAM surveys conducted Nationally.**
3.2.2 Healthy life expectancy at birth and 65 years

Healthy Life Expectancy (HLE) was selected because wellbeing in general and the absence of other medical conditions in particular, will tend to impact positively on the likelihood of people presenting with possible cancer symptoms; the hypothesis being that the presence of other conditions will mask cancer symptoms making it less likely for someone to recognise possible cancer symptoms and so delaying presentation of possible symptoms\textsuperscript{12}. As such we might anticipate residents with better overall healthy life expectancy to present with possible cancer symptoms earlier and hence have a higher probability of surviving following cancer diagnosis.

Healthy life expectancy (HLE) is based on subjective self-assessed health and adds value to life expectancy by estimating the average lifetime spent in a favourable state of health. The following charts show healthy life expectancy (2010 - 2012) at birth and at 65 years old.

\textsuperscript{12}\url{http://www.nature.com/bjc/journal/v113/n3/full/bjc2015164a.html} last accessed 16 October 2015
Figure 7: Healthy life expectancy at birth, 2010-12

Healthy Life Expectancy at Birth 2010-12

<table>
<thead>
<tr>
<th>Years</th>
<th>England</th>
<th>NHS West Essex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>63.5</td>
<td>67.0</td>
</tr>
<tr>
<td>Females</td>
<td>64.8</td>
<td>67.0</td>
</tr>
</tbody>
</table>

Source: Office for National Statistics

Healthy life expectancy at age 65

At age 65 years old, men in England could expect to live another 9.2 years in “Good” health compared with 10.2 years for men in West Essex. Women aged 65 years in England could expect to live 9.7 years in “good” health compared with 10.6 years for women in West Essex.
For both males and females, at birth and aged 65 years, healthy life expectancy in West Essex is higher than that for England.

### 3.3 Early diagnosis measures

NAEDI highlights that various studies comparing cancer survival across countries show that England does worse than comparable countries\(^\text{10}\). With the exception of breast cancer, the gap in survival between England and other countries was not narrowing (when considering patients diagnosed up to 2007). Stage of the disease at diagnosis is a major factor in survival and, for some cancers there is evidence that more patients in England are diagnosed at a later stage compared with other countries\(^\text{10}\).

In this section we consider:

1. Screening measures; breast and bowel
2. Use of the urgent referral pathway
3. Emergency presentations
4. Routes to diagnosis
5. Stage at diagnosis.

3.3.1 Screening measures; breast and bowel

Figures compiled by Cancer Research UK show that approximately one third (34%) of cancer cases diagnosed in females aged 50-74 are breast cancers, many of which are diagnosed through screening\textsuperscript{13}.

National screening programmes exist for specific age groups for breast cancer (women) and bowel cancer (men and women). In England, bowel screening has been shown to reduce the risk of dying from bowel cancer by a quarter in people who are screened\textsuperscript{14}.

The national screening programmes are subject to on-going quality assurance to maximise effectiveness. Where there is variation in the impacts of these programmes this will likely reflect both how the service is delivered and patient/ population characteristics.

The measures included here detail:

- Coverage (percentage of target group screened in the recommended screening period e.g. 3 years for breast screening) and
- Uptake (percentage of target population screened within 6 months of invitation) for both breast and bowel cancer screening programmes.

3.3.1.1 Breast cancer screening

The one-year net breast cancer survival measure for West Essex is lower than England and London as a whole (2012). This level of survival was amongst the lowest of London CCGs. Breast cancer screening coverage was very similar in West Essex compared with the England average over the

\textsuperscript{13}http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#ref-6
period 2012 – 2014. Uptake for breast cancer screening was slightly higher in West Essex than the England average.

**Figure 9: Females aged 50-70 screened for breast cancer in last 36 months**

Females, 50-70 screened for breast cancer in last 36 months (3 year coverage, %)

![Bar chart showing coverage percentages for females aged 50-70 screened for breast cancer in the UK from 2012 to 2014, with NHS West Essex CCG and England data.](chart1.png)

**Source:** NCIN, National GP Practice Profiles

**Figure 10: Females aged 50-70 screened for breast cancer within 6 months of invitation**

Females, 50-70 screened for breast cancer within 6 months invitation (uptake, %)

![Bar chart showing uptake percentages for females aged 50-70 screened for breast cancer within 6 months of invitation in the UK from 2012 to 2014, with NHS West Essex CCG and England data.](chart2.png)

**Source:** NCIN, National GP Practice Profiles
3.3.1.2 Bowel cancer screening

The narrative for bowel cancer broadly echoes that for breast cancer. West Essex residents in the 60-69 years target age group consistently have very similar coverage and uptake for bowel cancer screening to that for England as a whole.

Figure 11: Persons aged 60-69 screened for bowel cancer in last 30 months

![Bar chart showing bowel cancer screening coverage for West Essex CCG and England from 2012 to 2014.]

Source: NCIN, National GP Practice Profiles
3.3.2 Use of the urgent referral pathway

Cancer being diagnosed later is a major reason for poorer survival rates in the UK. The Improving Outcomes: A Strategy for Cancer\(^{11}\) estimates that, if patients were diagnosed at the same earlier stage as they are in other countries, up to 10,000 deaths could be avoided every year. The Strategy states that the challenge is clear: ‘In order to improve early diagnosis, we need to encourage people to recognise the symptoms and signs of cancer and seek advice from their doctor as soon as possible. We also need doctors to recognise these symptoms and (if appropriate) refer people urgently for specialist care.’ In a 2010 report, the National Audit Office identified that, amongst PCTs, there was almost a four-fold variation in the urgent cancer referral (two week wait) rate\(^ {15}\).

Use of the urgent referral pathway is central to the NAEDI pathway and a key focus of service improvement initiatives. Here we present:

• The rate of urgent referrals per 100,000 population: (the 2 week wait urgent referral pathway)
• The proportion of patients referred who are subsequently diagnosed with cancer (conversion rate); and
• The proportion of cancer cases in the practice that were referred through the two-week wait route (detection rate).

To better understand variations in use of the urgent referral pathway and to achieve earlier diagnosis, it is important that all three of these measures are considered together along with measures of the use of diagnostic tests.

The rate of urgent referrals per 100,000 population (referred using the two-week wait urgent referral pathway) increased in West Essex across the three years 2012 - 2014 and was consistently higher than that for England overall.

The following charts show the overall referrals and for each of the three main cancer site-specific referrals.

**Figure 13: Overall two-week-wait referrals**

![Overall 2-week-wait referrals chart](chart_url)

Source: NCIN, National GP Practice Profiles
Figure 14: Two-week-wait referrals with suspected breast cancer

Source: NCIN, National GP Practice Profiles

Figure 15: Two-week-wait referrals with suspected lower GI cancer

Source: NCIN, National GP Practice Profiles
Figure 16: Two-week-wait referrals with suspected lung cancer

The conversion rate is the percentage of the referrals that were found to have cancer and provides an indicator of the referral quality. The conversion rate was lower for West Essex at 8.1% in 2012 rising marginally to 8.2% in 2014 against the England figure of 9.5% in 2014.

Figure 17: Conversion rates (percentage of 2WW found to be cancer)
The detection rate tells us the percentage of all cancers that were identified through the two-week wait pathway. This was approximately 50% in West Essex over the period 2012 – 2014 with the rate consistently above the England rate.

Figure 18: Detection rate (number of new cancer cases treated)

The two-week wait referrals measures suggest there is room for improvement in the quality of referrals as indicated by the relatively low conversion rate. The relatively low performance in this area suggests scope for GP training and support.

3.3.3 Emergency presentations

Emergency presentations suggest late presentation and diagnosis and hence reduced chance of survival. High levels of emergency presentation indicate the need for improved awareness raising and support for the public to recognise and act on possible symptoms, and/or training for professionals (GPs) in symptom recognition and earlier referral. There is clearly a link between this and the previous section on two-week wait referrals and this theme is explored in this section and the following on ‘routes to diagnosis’.
This section includes:

- The National Cancer Intelligence Network (NCIN) proxy measure for emergency presentations for cancer; and
- the overall rate of emergency admissions.

### 3.3.3.1 Proxy measure for emergency presentations for cancer

The percentage of emergency presentations for cancer for West Essex residents is broadly comparable with that for England as a whole. The following chart shows less than a fifth of West Essex cancer patients presenting as emergencies. The percentage has fluctuated around this level during 2008 - 2012 and was consistently lower than that for England as a whole.

![Proxy measure for emergency presentations for cancer](image)

Source: NCIN, National GP Practice Profiles

### 3.3.3.2 Rate of emergency admissions with cancer

The rate of emergency admissions with cancer per 100,000 population was lower for West Essex than England as a whole for 2012 and 2013. In keeping

---

with the rate for England overall, there was a large drop in the rate in West Essex from 2012 to 2013.

**Figure 20: Rate of emergency admissions with cancer**

![Graph showing rate of emergency admissions with cancer](chart)

Source: NCIN, National GP Practice Profiles
3.3.4 Routes to diagnosis

The routes to diagnosis produced by the National Cancer Intelligence Network provided a valuable summary picture of the route patients take to diagnosis.

The data on emergency presentations gives valuable context and additional detail to the overall emergencies presentations measures in 3.3.3 above. In particular we can see from these figures (below) that:

- The proportion of breast cancers detected through screening was higher in West Essex than for England;
- The proportion of breast cancers detected through the managed route was lower in West Essex than for England and the ‘other’ route was higher;
- The proportion of colorectal cancers detected through each of the routes reported was very similar in West Essex compared with England; and
- The proportion of lung cancers detected through the managed route was lower in West Essex than for England.

There is a need to better understand the ‘other’ routes to diagnosis category; it has been suggested this might be the result of some patients being screened under private health care schemes.

The CCG is encouraged to explore means of increasing the proportion of cancer cases detected through managed routes.

Figure 21: Directly age-standardised rate per 100,000 population by route to diagnosis – breast cancer
Figure 22: Directly age-standardised rate per 100,000 population by route to diagnosis – colorectal cancer

<table>
<thead>
<tr>
<th></th>
<th>Screen-detected</th>
<th>Managed</th>
<th>Emergency presentation</th>
<th>Other</th>
<th>Number of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>2.8</td>
<td>10.3</td>
<td>10.2</td>
<td>1.9</td>
<td>58,057</td>
</tr>
<tr>
<td>Confidence interval</td>
<td>2.5</td>
<td>2.6</td>
<td>9.4</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>NHS West Essex CCG</td>
<td>2.0</td>
<td>27.1</td>
<td>9.5</td>
<td>3.6</td>
<td>838</td>
</tr>
<tr>
<td>Confidence interval</td>
<td>2.2</td>
<td>2.7</td>
<td>9.6</td>
<td>2.7</td>
<td></td>
</tr>
</tbody>
</table>

Source: NCIN

Figure 23: Directly age-standardised rate per 100,000 population by route to diagnosis – lung cancer

<table>
<thead>
<tr>
<th></th>
<th>Screen-detected</th>
<th>Managed</th>
<th>Emergency presentation</th>
<th>Other</th>
<th>Number of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>27.4</td>
<td>18.6</td>
<td>10.6</td>
<td>1.6</td>
<td>103,176</td>
</tr>
<tr>
<td>Confidence interval</td>
<td>27.4</td>
<td>27.7</td>
<td>10.5</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>NHS West Essex CCG</td>
<td>23.8</td>
<td>14.7</td>
<td>2.1</td>
<td>2.1</td>
<td>846</td>
</tr>
<tr>
<td>Confidence interval</td>
<td>23.8</td>
<td>26.1</td>
<td>10.9</td>
<td>1.6</td>
<td></td>
</tr>
</tbody>
</table>

Source: NCIN

3.3.5 Stage at diagnosis

The earlier cancer is detected the better the chance to improve survival. In this section we consider two measures:

- The proportion of the practice list on the practice cancer register (prevalent cancer cases); and
- Stage at diagnosis.

The first of these can be considered to be indicative of practice detection of cancers. Where a CCG has low percentages of residents on practice cancer registers it is anticipated that detection will be later and diagnosis will likely be at a later stage.

3.3.5.1 Prevalent cancer cases

The prevalent cancer cases (% of practice population on practice cancer registers) for West Essex residents in each of the three years 2012, 2013 and 2014 was higher than the England value.
Figure 24: Prevalent cancer cases

![Prevalent cancer cases (\% of practice population on practice cancer register)](chart)

*Source: NCIN, National GP Practice Profiles*

### 3.3.5.2 Cancer Staging

High-quality, comparable staging data on more than 80\% of all cases of the most common cancers is now available for the whole of the country, making England’s National Cancer Registration Service one of the most advanced anywhere in the world.

The latest staging data from the Cancer Outcomes and Services Dataset (COSD)\(^1\) shows higher percentages of cancers diagnosed at early stages (stages 1 and 2) for West Essex residents than for London overall. The proportion diagnosed with an unknown stage is lower than that across London.

These findings though should be treated with caution given the high proportions of cancers that were unknown (staging data not submitted by the hospital trust) or unstageable* at diagnosis.


* Unstageable should be assigned only after all efforts to identify the extent of the disease have been exhausted or the site or histology does not meet criteria for staging. Some cancers such as blood cancer are not stageable.
3.4 Diagnostics and treatment

A range of patient and service factors will affect stage at diagnosis. We have considered above patient knowledge and GP referrals (two-week wait). Once referred, the time patients wait for key diagnostics will have a bearing on the stage at diagnosis.

In this section we review:

- 6 week waits for key diagnostics;
- Access to diagnostics;
- Cancer waiting times; and
- Key provider treatment performance measures.

3.4.1 6 week waits for key diagnostics

Colonoscopy, flexible sigmoidoscopy and gastroscopy are key procedures used to identify bowel and gastrointestinal cancers (diagnostic) or treat conditions (therapeutic). We see from the following charts that although the values are variable, the proportion of people in West Essex waiting more than six weeks for colonoscopy, flexible sigmoidoscopy and gastroscopy...
procedures tended to be below the percentage for London and West Essex overall.

**Figure 26: Patients waiting over 6 weeks for a colonoscopy**

![Patients waiting 6+ weeks for a colonoscopy](source)

**Figure 27: Patients waiting over 6 weeks for a flexible sigmoidoscopy**

![Patients waiting 6+ weeks for a flexible sigmoidoscopy](source)
3.4.2 Access to diagnostic procedures

Here we review rates of key diagnostic procedures. The rates of access to colonoscopy, sigmoidoscopy and upper GI endoscopy procedures for West Essex residents tended to be lower than those for England over the period 2012 - 2013.

Figure 29: In-patient or day-case colonoscopy procedures

Source: NCIN, National GP Practice Profiles

Figure 30: In-patient or day-case sigmoidoscopy procedures

Source: NCIN, National GP Practice Profiles
These measures suggest action is needed by West Essex commissioners to increase access to these procedures.

### 3.4.3 Cancer waiting times

The time taken for a patient to be diagnosed and for treatment to begin will impact on chances of survival. In this section we review the following measures:

- 2 week wait:
- 31 day wait; and
- 62 day wait.

#### 3.4.3.1 2 week wait, all cancer (patients waiting within 14 days)

This measure is key in terms of early diagnosis. In 2013/14, 94.6% of patients in NHS West Essex CCG saw a specialist within two weeks. Whilst above the standard set for England (93%), this is lower than the England average (95.3%).
Figure 32: 2 week wait, all cancer

2 week wait - all cancer (patients waiting within 14 days)

Source: Cancer Waiting Times, NHS England

3.4.3.2 31-day (diagnosis to treatment) wait for first treatment, all cancers

This measure records patients receiving their first treatment within 31 days of the decision to treat. The standard set in England is 96%. We can see from the following chart that in 2013/14, 98.1% of cancer patients in NHS West Essex CCG received their first treatment within 31 days of a decision to treat. This is slightly lower than the England average (98.2%).

Figure 33: 31 day wait for first treatment

Source: Cancer Waiting Times, NHS England
3.4.3.3 62-day (urgent GP referral) wait for first treatment, all cancer

This measures the percentage of patients receiving their first treatment within 62 days of an urgent GP referral. The operational standard in England is 85%. In 2013/14, 82.8% of cancer patients in NHS West Essex CCG received their first treatment within 62 days of an urgent GP referral. This is lower than the England average (85.8%).

Figure 34: 62 day urgent GP referral for first treatment

Source: Cancer Waiting Times, NHS England
3.4.4 Key provider performance

In this section we provide results from the 2014 National Lung and Colorectal cancer audit\(^\text{18}\). Whilst the focus of the audit is provider performance, rather than specifically the treatment for the CCG’s residents, we can gain insights for West Essex residents by focussing on the main provider for West Essex, namely The Princess Alexandra.

The following table shows lung cancer performance at The Princess Alexandra to be above average (green ratings in 5 of the 6 measures). The percentage of non-small cell lung cancer (NSCLC) patients with cancer at stages 1a to 2b receiving surgery is considered a particular strong measure of provider performance and here The Princess Alexandra is higher than the London average (63% compared with 52% across London). The percentage of patients having CT prior to bronchoscopy is also considered a strong measure of provider performance and here The Princess Alexandra is lower than the London average (93.7% compared with 95% across London).

---

\(^{18}\) National Bowel Cancer Audit: [http://www.hscic.gov.uk/bowel](http://www.hscic.gov.uk/bowel)
## Table 4: Results by provider from the 2014 National Lung Cancer Audit, London Cancer and London Cancer Alliance

<table>
<thead>
<tr>
<th>Provider</th>
<th>% of discussed at patients MDT</th>
<th>% having CT prior to bronchoscopy</th>
<th>% of patients with a histological/cytological diagnosis</th>
<th>% CNS present at diagnosis</th>
<th>% of NSCLC 1a to 2b Receiving surgery 2011-13</th>
<th>% receiving Active treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barking, Havering and Redbridge</td>
<td>88.6%</td>
<td>74.2%</td>
<td>80.4%</td>
<td>52.9%</td>
<td>35.2%</td>
<td>50.4%</td>
</tr>
<tr>
<td>Barnet and Chase Farm</td>
<td>95.6%</td>
<td>77.0%</td>
<td>91.3%</td>
<td>92.3%</td>
<td>63.2%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Bart’s Health/Newham</td>
<td>97.2%</td>
<td>82.9%</td>
<td>88.9%</td>
<td>66.7%</td>
<td>41.7%</td>
<td>59.7%</td>
</tr>
<tr>
<td>Bart’s Health/RLH</td>
<td>96.7%</td>
<td>95.3%</td>
<td>90.9%</td>
<td>59.5%</td>
<td>62.2%</td>
<td>58.7%</td>
</tr>
<tr>
<td>Bart’s Health/Whipps Cross</td>
<td>91.8%</td>
<td>90.5%</td>
<td>86.1%</td>
<td>77.0%</td>
<td>45.2%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Chelsea and Westminster</td>
<td>94.4%</td>
<td>90.9%</td>
<td>91.7%</td>
<td>58.3%</td>
<td>59.5%</td>
<td>61.1%</td>
</tr>
<tr>
<td>Croydon Healthcare NHS Trust</td>
<td>97.0%</td>
<td>92.5%</td>
<td>85.1%</td>
<td>96.7%</td>
<td>39.7%</td>
<td>61.2%</td>
</tr>
<tr>
<td>Ealing Hospital NHS Trust</td>
<td>98.5%</td>
<td>82.4%</td>
<td>55.4%</td>
<td>66.2%</td>
<td>31.0%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Epsom and St Helier Uni. NHS</td>
<td>76.2%</td>
<td>92.5%</td>
<td>73.5%</td>
<td>40.9%</td>
<td>32.9%</td>
<td>59.7%</td>
</tr>
<tr>
<td>Guys and St Thomas’ NHS FT</td>
<td>100.0%</td>
<td>94.8%</td>
<td>100.0%</td>
<td>55.0%</td>
<td>56.5%</td>
<td>87.4%</td>
</tr>
<tr>
<td>Imperial College Healthcare NHS</td>
<td>100.0%</td>
<td>95.9%</td>
<td>86.7%</td>
<td>51.8%</td>
<td>57.5%</td>
<td>73.1%</td>
</tr>
<tr>
<td>Kings College Hospital NHS FT</td>
<td>99.3%</td>
<td>88.1%</td>
<td>84.7%</td>
<td>86.1%</td>
<td>56.7%</td>
<td>61.3%</td>
</tr>
<tr>
<td>Kingston Hospital NHS Trust</td>
<td>95.9%</td>
<td>90.9%</td>
<td>76.2%</td>
<td>59.0%</td>
<td>60.0%</td>
<td>60.7%</td>
</tr>
<tr>
<td>Lewisham</td>
<td>97.7%</td>
<td>79.1%</td>
<td>78.3%</td>
<td>67.1%</td>
<td>44.2%</td>
<td>58.9%</td>
</tr>
<tr>
<td>North Middlesex</td>
<td>97.8%</td>
<td>100.0%</td>
<td>80.0%</td>
<td>97.8%</td>
<td>45.9%</td>
<td>64.4%</td>
</tr>
<tr>
<td>North West London</td>
<td>96.8%</td>
<td>95.5%</td>
<td>86.2%</td>
<td>63.8%</td>
<td>71.2%</td>
<td>67.0%</td>
</tr>
<tr>
<td>South London Healthcare</td>
<td>95.9%</td>
<td>91.1%</td>
<td>81.8%</td>
<td>76.5%</td>
<td>36.8%</td>
<td>62.4%</td>
</tr>
<tr>
<td>St George’s Healthcare NHS</td>
<td>84.6%</td>
<td>81.8%</td>
<td>83.8%</td>
<td>35.3%</td>
<td>53.7%</td>
<td>56.6%</td>
</tr>
<tr>
<td>The Hillingdon NHS Foundation</td>
<td>93.5%</td>
<td>97.9%</td>
<td>58.1%</td>
<td>79.0%</td>
<td>51.4%</td>
<td>52.4%</td>
</tr>
<tr>
<td>The Homerton</td>
<td>100.0%</td>
<td>94.7%</td>
<td>83.7%</td>
<td>77.2%</td>
<td>44.3%</td>
<td>59.8%</td>
</tr>
<tr>
<td>The Princess Alexandra</td>
<td>99.4%</td>
<td>93.7%</td>
<td>81.6%</td>
<td>88.6%</td>
<td>63.0%</td>
<td>64.6%</td>
</tr>
<tr>
<td>The Royal Brompton &amp; Harefield</td>
<td>21.7%</td>
<td>95.8%</td>
<td>100.0%</td>
<td>56.5%</td>
<td>86.4%</td>
<td>87.0%</td>
</tr>
<tr>
<td>The Royal Free</td>
<td>100.0%</td>
<td>96.2%</td>
<td>90.3%</td>
<td>97.1%</td>
<td>79.6%</td>
<td>63.1%</td>
</tr>
<tr>
<td>The Whittington</td>
<td>97.8%</td>
<td>96.3%</td>
<td>76.1%</td>
<td>37.0%</td>
<td>51.0%</td>
<td>65.2%</td>
</tr>
<tr>
<td>UCLH</td>
<td>95.6%</td>
<td>94.4%</td>
<td>88.5%</td>
<td>55.0%</td>
<td>59.8%</td>
<td>85.5%</td>
</tr>
<tr>
<td>West Middlesex University NHS</td>
<td>98.9%</td>
<td>97.3%</td>
<td>78.7%</td>
<td>1.1%</td>
<td>54.9%</td>
<td>45.7%</td>
</tr>
<tr>
<td><strong>London TOTAL</strong></td>
<td>95.0%</td>
<td>95.0%</td>
<td>75.0%</td>
<td>80.0%</td>
<td>52.0%</td>
<td>60.0%</td>
</tr>
</tbody>
</table>

The following tables show colorectal cancer performance (tables 5 and 6). Colorectal cancer performance at The Princess Alexandra (table 5) is above average (green ratings in 4 of the 6 measures). The adjusted 90-day post op mortality is strong measure of colorectal cancer provider performance and here The Princess Alexandra is higher than the London and the audits average (8.3% compared with 4.6%). The adjusted 18-month stoma rate is also a key performance area and here The Princess Alexandra is lower than the London average (44% compared with 51% across London).

Table 5: Results by provider from the 2014 National Colorectal Cancer Audit, London Cancer

<table>
<thead>
<tr>
<th></th>
<th>Adjusted 90 day post op Mortality</th>
<th>% LOS &gt; 5 Days</th>
<th>% of operations attempted laparoscopically</th>
<th>% who underwent major resection</th>
<th>Adjusted 2 year mortality</th>
<th>Adjusted 18 month stoma rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnet and Chase Farm</td>
<td>3.7%</td>
<td>68.6%</td>
<td>67.8%</td>
<td>64.0%</td>
<td>18.6%</td>
<td>62.0%</td>
</tr>
<tr>
<td>Bart’s Health</td>
<td>4.6%</td>
<td>75.2%</td>
<td>85.0%</td>
<td>65.5%</td>
<td>33.4%</td>
<td>46.0%</td>
</tr>
<tr>
<td>Barking, Havering &amp; Redbridge NHST</td>
<td>6.8%</td>
<td>73.5%</td>
<td>52.9%</td>
<td>61.5%</td>
<td>19.1%</td>
<td>54.0%</td>
</tr>
<tr>
<td>North Middlesex</td>
<td>4.6%</td>
<td>90.9%</td>
<td>84.1%</td>
<td>68.8%</td>
<td>36.1%</td>
<td>0.0%</td>
</tr>
<tr>
<td>The Homerton</td>
<td>5.2%</td>
<td>84.4%</td>
<td>52.2%</td>
<td>64.8%</td>
<td>23.4%</td>
<td>28.0%</td>
</tr>
<tr>
<td>The Princess Alexandra</td>
<td>8.3%</td>
<td>42.9%</td>
<td>74.1%</td>
<td>74.2%</td>
<td>32.1%</td>
<td>44.0%</td>
</tr>
<tr>
<td>The Whittington</td>
<td>4.4%</td>
<td>78.7%</td>
<td>71.4%</td>
<td>60.0%</td>
<td>20.2%</td>
<td>45.0%</td>
</tr>
<tr>
<td>The Royal Free</td>
<td>8.8%</td>
<td>74.1%</td>
<td>53.2%</td>
<td>Not reported</td>
<td>39.0%</td>
<td></td>
</tr>
<tr>
<td>UCLH</td>
<td>10.1%</td>
<td>80.6%</td>
<td>58.0%</td>
<td>66.3%</td>
<td>25.2%</td>
<td>62.0%</td>
</tr>
<tr>
<td>London Cancer</td>
<td>5.6%</td>
<td>75.6%</td>
<td>67.8%</td>
<td>64.7%</td>
<td>24.4%</td>
<td>49.0%</td>
</tr>
<tr>
<td><strong>Audit Average</strong></td>
<td>4.6%</td>
<td>69.0%</td>
<td>61.0%</td>
<td>66.0%</td>
<td>24.0%</td>
<td>51.0%</td>
</tr>
</tbody>
</table>

Table 6: Results by provider from the 2014 National Colorectal Cancer Audit, London Cancer Alliance

<table>
<thead>
<tr>
<th>Provider</th>
<th>Adjusted 90 day mortality</th>
<th>% LOS &gt; 5 Days</th>
<th>% operations attempted laparoscopically</th>
<th>Adjusted 90 day unplanned readmission rate %</th>
<th>Adjusted 2 year mortality</th>
<th>Adjusted 18 month stoma rate using HES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chelsea and Westminster</td>
<td>5.6%</td>
<td>87.0%</td>
<td>47.9%</td>
<td>26.7%</td>
<td>19.4%</td>
<td>56.0%</td>
</tr>
<tr>
<td>Croydon Healthcare NHS Trust</td>
<td>9.9%</td>
<td>Data not submitted</td>
<td>41.3%</td>
<td>8.1%</td>
<td>21.0%</td>
<td>38.0%</td>
</tr>
<tr>
<td>Ealing Hospital NHS Trust</td>
<td>1.9%</td>
<td>90.2%</td>
<td>73.8%</td>
<td>31.0%</td>
<td>22.1%</td>
<td>53.0%</td>
</tr>
<tr>
<td>Epsom and St Helier University NHS Trust</td>
<td>5.2%</td>
<td>82.1%</td>
<td>82.1%</td>
<td>20.1%</td>
<td>24.0%</td>
<td>33.0%</td>
</tr>
<tr>
<td>Guys and St Thomas' NHS FT</td>
<td>3.8%</td>
<td>Data not submitted</td>
<td>100.0%</td>
<td>21.3%</td>
<td>17.5%</td>
<td>74.0%</td>
</tr>
<tr>
<td>Imperial College Healthcare NHS Trust</td>
<td>0.8%</td>
<td>95.0%</td>
<td>83.3%</td>
<td>25.4%</td>
<td>19.5%</td>
<td>51.0%</td>
</tr>
<tr>
<td>Kings College Hospital NHS FT</td>
<td>4.3%</td>
<td>80.9%</td>
<td>77.1%</td>
<td>14.3%</td>
<td>18.8%</td>
<td>61.0%</td>
</tr>
<tr>
<td>Kingston Hospital NHS Trust</td>
<td>7.8%</td>
<td>72.3%</td>
<td>36.6%</td>
<td>25.7%</td>
<td>22.1%</td>
<td>32.0%</td>
</tr>
<tr>
<td>Lewisham</td>
<td>0.0%</td>
<td>69.4%</td>
<td>18.2%</td>
<td>12.0%</td>
<td>30.0%</td>
<td>55.0%</td>
</tr>
<tr>
<td>North West London</td>
<td>13.7%</td>
<td>100.0%</td>
<td>83.3%</td>
<td>14.6%</td>
<td>18.3%</td>
<td>29.0%</td>
</tr>
<tr>
<td>St Georges Healthcare NHS Trust</td>
<td>4.6%</td>
<td>61.5%</td>
<td>65.1%</td>
<td>22.1%</td>
<td>n/a</td>
<td>26.0%</td>
</tr>
<tr>
<td>South London Healthcare</td>
<td>4.3%</td>
<td>71.9%</td>
<td>61.3%</td>
<td>19.8%</td>
<td>26.0%</td>
<td>31.0%</td>
</tr>
<tr>
<td>The Hillingdon NHS FT</td>
<td>2.0%</td>
<td>78.0%</td>
<td>58.3%</td>
<td>31.3%</td>
<td>31.7%</td>
<td>61.0%</td>
</tr>
<tr>
<td>The Royal Marsden</td>
<td>0.0%</td>
<td>85.7%</td>
<td>52.9%</td>
<td>10.2%</td>
<td>7.9%</td>
<td>25.0%</td>
</tr>
<tr>
<td>West Middlesex University NHS Trust</td>
<td>5.2%</td>
<td>67.3%</td>
<td>51.0%</td>
<td>22.7%</td>
<td>21.6%</td>
<td>46.0%</td>
</tr>
<tr>
<td>LCA Total</td>
<td>4.3%</td>
<td>78.8%</td>
<td>52.7%</td>
<td>20.6%</td>
<td>22.0%</td>
<td>54.0%</td>
</tr>
<tr>
<td><strong>Audit Average</strong></td>
<td><strong>4.6%</strong></td>
<td><strong>69.0%</strong></td>
<td><strong>61.0%</strong></td>
<td><strong>19.8%</strong></td>
<td><strong>24.0%</strong></td>
<td><strong>51.0%</strong></td>
</tr>
</tbody>
</table>

Here we provide a recap of the key points raised in part 2 of this report:

- In West Essex, in 2009/10, the Cancer Awareness Measure found that 41% of people surveyed could recall a symptom of cancer. West Essex is ranked as 17th out of the 22 CCGs with survey results.

- For both males and females, at birth and aged 65 years, healthy life expectancy in West Essex is higher than that for England.

- Breast cancer screening coverage was very similar in West Essex compared with the England average over the period 2012 – 2014. Uptake for breast cancer screening was slightly higher in West Essex than the England average.

- West Essex residents in the 60-69 years target age group consistently have very similar coverage and uptake for bowel cancer screening to that for England as a whole.

- The rate of urgent referrals per 100,000 population (referred using the two-week wait urgent referral pathway) increased in West Essex across the three years 2012 - 2014 and was consistently higher than that for England overall.

- The conversion rate is the percentage of referrals that were found to have cancer and provides an indicator of referral quality. The conversion rate was lower for West Essex at 8.1% in 2012 rising marginally to 8.2% in 2014 against the England figure of 9.5% in 2014.

- The detection rate tells us the percentage of all cancers that were identified through the two-week wait pathway. This was approximately 50% in West Essex over the period 2012 – 2014 with the rate consistently above the England rate.
• Less than a fifth of West Essex cancer patients presented as emergencies according to the NCIN proxy measure. The percentage has fluctuated around this level during 2008 - 2012 and was consistently lower than that for England as a whole

• The rate of emergency admissions with cancer per 100,000 population was lower for West Essex than England as a whole for 2012 and 2013. In keeping with the rate for England overall, there was a large drop in the rate in West Essex from 2012 to 2013

• The proportion of breast cancers detected through screening was higher in West Essex than for England;

  The proportion of breast cancers detected through the managed route was lower in West Essex than for England and the ‘other’ route was higher;

• The proportion of colorectal cancers detected through each of the routes reported was very similar in West Essex compared with England

• The proportion of lung cancers detected through the managed route was lower in West Essex than for England

• The prevalent cancer cases (% of practice population on practice cancer registers) for West Essex residents in each of the three years 2012, 2013 and 2014 was higher than the England value

• The latest staging data from the Cancer Outcomes and Services Dataset (COSD) shows higher percentages of cancers diagnosed at early stages (stages 1 and 2) for West Essex residents than for London overall. The proportion diagnosed with an unknown stage is lower than that across London
NHS West Essex CCG

- The proportion of people in West Essex waiting more than six weeks for colonoscopy, flexible sigmoidoscopy and gastroscopy procedures tended to be below the proportion for London and West Essex overall.

- The rates of access to colonoscopy, sigmoidoscopy and upper GI endoscopy procedures for West Essex residents tended to be lower than those for England over the period 2012 - 2013.

- In 2013/14, 94.6% of patients in NHS West Essex CCG saw a specialist within two weeks. Whilst above the standard set for England (93%), this is lower than the England average (95.3%).

- In 2013/14, 98.1% of cancer patients in NHS West Essex CCG received their first treatment within 31 days of a decision to treat. This is lower than the England average (98.2%).

- In 2013/14, 82.8% of cancer patients in NHS West Essex CCG received their first treatment within 62 days of an urgent GP referral. This is lower than the England average (85.8%).

- The percentage of non-small cell lung cancer (NSCLC) patients with cancer at stages 1a to 2b receiving surgery is considered a particular strong measure of lung cancer provider performance and here The Princess Alexandra is higher than the London average (63% compared with 52% across London).

- The percentage of patients having CT prior to bronchoscopy is also considered a strong measure of lung cancer provider performance and here The Princess Alexandra is lower than the London average (93.7% compared with 95% across London).

- The adjusted 90-day post op mortality is strong measure of colorectal cancer provider performance and here The Princess Alexandra is
higher than the London and the audits average (8.3% compared with 4.6%)

• The adjusted 18-month stoma rate is a key colorectal cancer provider performance area and here The Princess Alexandra is lower than the London average (44% compared with 51% across London).
4. **Next steps**

In this review we have examined over two dozen measures related to survival, screening, diagnosis and management of cancer patients, in particular the three main cancers - breast, colorectal and lung.

The key findings and suggested actions are detailed in the report and repeated in summary sections (at the end of Parts 1 and 2) and additionally in the Executive Summary.

It is hoped that CCGs will be engaged through this report and encouraged to consider what can be done to improve further survival from cancer. More detailed data may be available to enable supplementary analyses and TCST for London will assist with this as resources permit.

Finally, the TCST for London welcome your feedback on this report.